Comparison of Two Different Laparoscopic Donor Nephrectomy With Vaginal Extraction Techniques—A Single-Center Experience

Objective

The aim of this study was to compare the results of standard laparoscopic donor nephrectomy with vaginal extraction (SLDN-VE) and laparoendoscopic single-site donor nephrectomy with vaginal extraction (LESSDN-VE).

Comparison of Buccal Infiltration of 4% Articaine With 1?:?100,000 and 1?:?200,000 Epinephrine for Extraction of Maxillary Third Molars With Pericoronitis: A Pilot Study

We compared the buccal infiltration of 4% articaine with 1 : 100,000 or 1 : 200,000 epinephrine without a palatal injection for the extraction of impacted maxillary third molars with chronic pericoronitis. This prospective, double-blind, controlled clinical trial involved 30 patients between the ages of 15 and 46 years who desired extraction of a partially impacted upper third molar with pericoronitis. Group 1 (15 patients) received 4% articaine with 1 : 100,000 epinephrine and group 2 (15 patients) received 4% articaine with 1 : 200,000 epinephrine by buccal infiltration. None of the patients in group 1 reported pain, but 3 patients in group 2 reported pain, which indicated a need for a supplementary palatal injection. The palatal injections were all successful in eliminating the pain. Two additional patients in group 2 experienced pain when the suture needle penetrated their palatal mucosa. Based on these results, 4% articaine with 1 : 100,000 epinephrine was found to be more effective for the removal of upper third molars in the presence of pericoronitis than 4% articaine hydrochloride with 1 : 200,000 epinephrine when only a buccal infiltration was used.Key Words: Articaine, Epinephrine, Molar extractionMaxillary third molar extraction is generally straightforward, due to the plasticity of the maxillary bone and to the low resistance to extraction movements. Nevertheless, the anesthetic technique needed for such extraction may be extremely uncomfortable because it requires palatal mucosal anesthesia.^1,2Studies have suggested that articaine has good diffusion through the hard and soft tissues, eliminating the need for the palatal injection in maxillary third molar extractions.^3–6 However, the anesthetic effect may be decreased or neutralized because the inflammation and low tissue pH affects tissue diffusion of the anesthetic, making the drug less effective.^7–9Pericoronitis is the most frequent inflammatory pathology associated with third molars and is caused by a combination of factors including trauma and food impaction with subsequent bacterial colonization and infection.^1,10–13 Clinically, it is characterized by the presence of erythema, swelling, and even ulceration in some cases.^1,14 The management of pericoronitis varies. Many authors have recommended using antibiotic therapy when there are signs of acute infection with systemic involvement such as fever. In cases of chronic or nonacute clinical manifestations, treatment should be limited to antiseptic mouthwashes, irrigation, and anti-inflammatory and/or anesthetic medication. Surgically, the usual treatment is the extraction of the impacted tooth.^1,11–15The aim of the present study was to evaluate the differences between articaine hydrochloride with 1 : 100,000 and 1 : 200,000 epinephrine (adrenaline) administered by buccal infiltration alone (without palatal infiltration) for the removal of impacted upper third molar teeth with pericoronitis.     

Cemented Versus Cementless Total Knee Arthroplasty in Obese Patients With Body Mass Index ≥35 kg/m2: A Contemporary Analysis of 812 Patients

BackgroundCemented total knee arthroplasty (TKA) has been shown to have higher failure rates in obese patients, and cementless TKA may provide more durable fixation. This study compared outcomes and survivorship of obese patients undergoing cemented and cementless TKA of the same modern design.MethodsWe identified a consecutive series of 406 primary cementless TKA performed in obese patients with body mass index (BMI) ≥35 kg/m² in 2013-2018. Each case was matched 1:1 with 406 cemented TKA based on age, sex, BMI, bearing surface, and year of surgery. Knee Injury and Osteoarthritis Outcome Score for Joint Replacement and Short Form-12 were collected preoperatively, at 6 months and 2 years. Implant survivorship was recorded at mean 4.0 years (range 2.0-7.8).ResultsThere was no difference in mean BMI between the cemented (38.6 ± 3.4 kg/m²; range, 35-60) and cementless cohorts (38.7 ± 3.3 kg/m²; range, 35-54; P = .706). Both groups had similar final postoperative scores and improvement in scores at 2 years. Furthermore, a similar percentage met the minimal clinically important difference (Knee Injury and Osteoarthritis Outcome Score for Joint Replacement, 70.0% vs 71.2%, P = .700; Short Form-12 Physical, 74.1% vs 70.4%, P = .240). Both groups demonstrated high 7-year survivorship free from aseptic revision (99.0% vs 99.5%, P = .665).ConclusionObese patients with BMI ≥35 kg/m² undergoing cementless and cemented TKA of the same modern design had similar outcomes and survivorship at early to mid-term follow-up. Continued surveillance of this high-risk population is necessary.     

Risk of Incident Atrial Fibrillation With Zoledronic Acid Versus Denosumab: A Propensity Score–Matched Cohort Study

Zoledronic acid (ZA) is an effective agent in osteoporosis and malignancy-related bone disease but may be associated with increased risk of atrial fibrillation (AF), although current studies disagree on this risk. To examine the risk of incident AF among patients receiving ZA compared with denosumab in the first year of treatment, we performed a new-user, active comparator cohort study including privately insured Americans between January 1, 2010, and June 30, 2019. Individuals aged ≥50 years without known arrhythmia or advanced kidney disease who initiated ZA were 1:1 propensity score (PS)-matched to individuals initiating denosumab in separate osteoporosis and malignancy cohorts. The primary outcome was incident diagnosis of AF (≥ 1 inpatient or ≥ 2 outpatient diagnostic codes) over 1 year. Secondary outcomes included stroke/transient ischemic attack (TIA) and nonvertebral fracture. In the osteoporosis cohort (n = 16,235 pairs), mean age was 71 years, and 93% were female. There was higher risk of AF with ZA compared with denosumab over 1 year (incidence rate [IR] = 18.6 versus 14.9 per 1000 person-years; hazard ratio [HR] = 1.25; 95% confidence interval [CI] 1.04 to 1.50). In the malignancy cohort (n = 7732 pairs), mean age was 70 years, and 66% were female. There was a numerically higher, albeit not statistically significant, risk of AF with ZA compared with denosumab over 1 year (IR = 46.9 versus 39.0 per 1000 person-years; HR = 1.19; 95% CI 1.00 to 1.43; p = 0.06). No difference in stroke/TIA rates occurred. In the malignancy cohort, ZA was less effective than denosumab at preventing nonvertebral fractures (HR = 1.32; 95% CI 1.01 to 1.74). Compared with denosumab, ZA treatment for osteoporosis and possibly for malignancy-related bone disease is associated with modestly increased risk of incident AF in the first year of treatment. © 2020 American Society for Bone and Mineral Research (ASBMR).     

Atomised intranasal midazolam spray as premedication in pediatric patients: comparison between two doses of 0.2 and 0.3?mg/kg

Purpose

Midazolam premedication administered by the intranasal route is noninvasive with good bioavailability. Atomised intranasal midazolam spray ensures accurate drug dosage and better patient acceptability, with rapid onset of action and virtually complete absorption.

Methods

Sixty pediatric patients scheduled for elective surgeries were administered atomised intranasal midazolam. Two doses of midazolam, of 0.2 and 0.3?mg/kg, were compared. Children were observed for achieving satisfactory sedation and separation scores, and face mask acceptance.

Results

At 10 and 20?min of nasal administration, 70 and 76% of the children, respectively, in the 0.3?mg/kg dose group, while 40 and 63% of the children, respectively, in the 0.2?mg/kg group were adequately sedated. Similarly, at 10 and 20?min after administration, 66.6 and 73.3% of children, respectively, in the 0.3?mg/kg group, and 30 and 60% in the 0.2?mg/kg group were easily separated from their parents. With regard to face mask acceptance, 33.3% of patients in the 0.3?mg/kg group and 16.6% in the 0.2?mg/kg group accepted the mask easily.

Conclusion

Atomised midazolam at 0.3?mg/kg is safe, and achieves faster sedation and better separation scores as compared to 0.2?mg/kg.     

A Prospective,Randomized, Double-Blind Comparison of 2% Lidocaine With 1?:?100,000 Epinephrine, 4% Prilocaine With 1?:?200,000 Epinephrine,and 4% Prilocaine for Maxillary Infiltrations

The purpose of this prospective, randomized, double-blind crossover study was to evaluate the anesthetic efficacy of 2% lidocaine with 1 : 100,000 epinephrine, 4% prilocaine with 1 : 200,000 epinephrine, and 4% prilocaine in maxillary lateral incisors and first molars. Sixty subjects randomly received, in a double-blind manner, maxillary lateral incisor and first molar infiltrations of 1.8 mL of 2% lidocaine with 1 : 100,000 epinephrine, 1.8 mL of 4% prilocaine with 1 : 200,000 epinephrine, and 1.8 mL of 4% prilocaine, at 3 separate appointments spaced at least 1 week apart. The teeth were pulp-tested in 3-minute cycles for a total of 60 minutes. Anesthetic success (ie, obtaining 2 consecutive 80 readings with the electric pulp tester) and onset of pulpal anesthesia were not significantly different between 2% lidocaine with 1 : 100,000 epinephrine, 4% prilocaine with 1 : 200,000 epinephrine, and 4% prilocaine for the lateral incisor and first molar. For both lateral incisor and first molar, 4% prilocaine with 1 : 200,000 epinephrine and 2% lidocaine with 1 : 100,000 epinephrine were equivalent for incidence of pulpal anesthesia. However, neither anesthetic agent provided an hour of pulpal anesthesia. For both lateral incisor and first molar, 4% prilocaine provided a significantly shorter duration of pulpal anesthesia compared with 2% lidocaine with 1 : 100,000 epinephrine and 4% prilocaine with 1 : 200,000 epinephrine.     

Is There a Difference Between Patients With Peak Oxygen Consumption Below 10 mL/kg/min Versus Between 10 and 14 mL/kg/min? Does the “Grey Zone” Really Exist?

Background

Cardiopulmonary exercise testing is an important component of evaluation when orthotopic heart transplantation (OHT) is considered for chronic heart failure (CHF) patients. However there is a question about the accuracy of interpretations of peak oxygen consumption (VO₂max) used at present.

Materials and Methods

We analyzed 302 CHF patients stratified into 3 groups according to VO₂max (mL/kg/min): group 1 = <10 (n = 37); group 2 = 10-14 (n = 121) and group 3 = >14 (n = 144). We compared the mortality rate, the OHT rate, time to OHT, time to death and pulmonary function tests (PFT) among the groups using ANOVA Kruskal-Wallis tests for analysis in Statistica 7.1.

Results

No important differences were observed between groups 1 and 2 (P > .05), but first in comparison with group 3 (P < .05) in terms of mortality (48.6% vs 33.1% vs 21.5%), number of OHT (24.3% vs 32.2% vs 14.6%), time to death (15.4 vs 16.6 vs 34.4 months) or PFT results (forced expiratory volume in the first second forced vital capacity and peak expiratory flow, all as direct or as percent of normal values). In contrast, time to OHT (4.6 vs 6.9 vs 10.9 months) and percent of normal vital capacity (72% vs 81% vs 91%) differed significantly among all groups (P < .05).

Conclusion

Patients with VO₂max between 10 and 14 or <10 mL/kg/min are at similar risk of death.     

A Paradox in Individual Versus National Mental Health Vulnerability: Are Higher Resource Levels Associated With Higher Disorder Prevalence?

An earlier study (Dückers, Alisic, & Brewin, 2016) found that countries with greater social and economic resources were characterized by a higher lifetime prevalence of posttraumatic stress disorder (PTSD). Here, we present a similar analysis of national population survey data to examine this vulnerability paradox in relation to other disorders. We predicted the lifetime prevalence of any mental health disorder (i.e., anxiety, mood, substance, and externalizing disorders) in 17 countries based on trauma exposure and country vulnerability data. A substantial proportion of variance in all disorder categories, 32.9% to 53.9%, could be explained by trauma exposure. Explained variance increased by 5 and up to 40 percentage points after adding the variable of vulnerability to the equation. Higher exposure and lower vulnerability levels were accompanied by a higher prevalence in any mental disorder, with the largest effect size in mood disorders (R² = .76). The interaction between exposure and vulnerability did not explain significant additional variance as it did for PTSD. Because a PTSD diagnosis links psychological, physical, and functional symptoms explicitly to trauma exposure, this might mean that populations in less‐vulnerable countries are more likely to attribute health complaints to exposure. The results of this study suggest that country‐level data can help to better explain the multilayered mechanisms of resilience and vulnerability in the context of trauma.     

Diabetic Driving Studies—Part 2: A Comparison of Brake Response Time Between Drivers With Diabetes With and Without Lower Extremity Sensorimotor Neuropathy

We have previously demonstrated an abnormally delayed mean brake response time and an increased frequency of abnormally delayed brake responses in a group of neuropathic drivers with diabetes compared with a control group of drivers with neither diabetes nor lower extremity neuropathy. The objective of the present case-control study was to compare the mean brake response time between 2 groups of drivers with diabetes with and without lower extremity sensorimotor neuropathy. The braking performances of the participants were evaluated using a computerized driving simulator with specific measurement of the mean brake response time and the frequency of the abnormally delayed brake responses. We compared a control group of 25 active drivers with type 2 diabetes without lower extremity neuropathy and an experimental group of 25 active drivers with type 2 diabetes and lower extremity neuropathy from an urban U.S. podiatric medical clinic. The experimental group demonstrated an 11.49% slower mean brake response time (0.757 ± 0.180 versus 0.679 ± 0.120 second; p < .001), with abnormally delayed reactions occurring at a greater frequency (57.5% versus 35.0%; p < .001). Independent of a comparative statistical analysis, diabetic drivers with neuropathy demonstrated a mean brake response time slower than a suggested safety threshold of 0.70 second, and diabetic drivers without neuropathy demonstrated a mean brake response time faster than this threshold. The results of the present investigation provide evidence that the specific onset of lower extremity sensorimotor neuropathy associated with diabetes appears to impart a negative effect on automobile brake responses.     

Quality of Life After Surgical Treatment of Early Barrett’s Cancer: A Prospective Comparison of the Ivor-Lewis Resection Versus the Modified Merendino Resection

Introduction

The Merendino (MER) procedure has been evaluated as an alternative to transthoracic esophageal resection (TER) for early stage Barrett’s carcinoma. Apart from reducing morbidity and mortality, improvements concerning postoperative health-related quality of life (HRQL) have been postulated. The aim of our study was to compare HRQL between these procedures.

Materials and methods

Between July 2000 and July 2007, 117 patients with early Barrett’s carcinoma underwent surgery. Patients with tumor recurrence were excluded from the study. HRQL was assessed 1 and 2 years after surgery using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (EORTC-QLQ-C30) and the QLQ-OES18 module. Patients recently diagnosed with early Barrett’s carcinoma served as controls. Symptoms that showed a difference of more than ten between the control and the study groups were considered clinically relevant and were tested for significant differences between the study groups using the Mann–Whitney U test (p < 0.05).

Results

The response rates for the questionnaires ranged between 70 and 93 %. In the MER group, more items reflected a clinical relevant impairment of HRQL than in the TER group. Significant complaints in the MER group included nausea/vomiting, appetite loss, local pain, difficulties with social eating, and choking. Moreover, we found a significant restriction concerning global health and emotional and social functioning in this group 1 year after surgery. 2 years postoperatively, hardly any differences between the operative techniques could be detected. The only symptom in favor of the MER procedure was a better dysphagia score postoperatively.

Conclusion

Our study suggests that MER procedure is not superior to subtotal esophagectomy with regard to HRQL.